Mark Engelman and Michael Kock
Head of Intellectual Property, Hardwicke Chambers, Research Associate in IP University of Cambridge, UK, Legal Correspondent The Pharma Letter, Director MRG & Associates Ltd Head of Intellectual Property, Syngenta AG
Scientific Tracks Abstracts: Biochem Mol biol J
A discussion concerning the legal recognition of copyright rather than patent in DNA nucleotide sequences as they relate to Mechano growth factor. A discussion of Emergent Genetics India Pvt. Ltd V Shailendra Shivam, Ravindra. With this case we finally have a ruling on the interesting debate on copyrightability of DNA sequences which had been brewing for some time. Keywords� copyright, DNA Sequences, intellectual property
Mark Engelman is a pharmacologist (King’s Lond.), trained as a barrister. Having practiced with in 2 firms of IP specialist solicitors, 2 major multinationals, he is head of IP at Hardwicke, a set of barristers. He has been non-executive directors of companies which include Alexander McQueen and the patent owner of the Mechano Growth Factor suit of patents. He acts for numerous multinationals. He is a Research Associate as St Edmunds College Cambridge in IP and Bencher of the Hon Soc. of Gray’s Inn, London. He is he legal correspondent for The Pharma Letter
Email:mark.engelman@hardwicke.co.uk
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 